Case Studies in Anal Cancer Prevention

People with HIV (PWH) are at disproportionate risk for anal cancer and should routinely be screened to detect anal cancer precursors that can be treated to reduce cancer risk. By participating in this webinar, you will have the opportunity to enhance patient care by gaining a deeper understanding of the recently updated anal cancer screening guidelines for PWH. This webinar will further equip you with essential knowledge on how to implement these guidelines with your care team, helping to ensure PWH in your practice are receiving comprehensive, high-quality, evidence-based care. Additionally, the webinar will help you stay current with best practices in the ever-evolving field of HIV care. By learning about the latest effective primary prevention measures, you can ensure that your clinical practices are aligned with current guidelines. Lastly, the webinar emphasizes team-based care, offering valuable insights on collaborating with multidisciplinary teams to optimize care coordination and support for patients with HIV.

What You Can Expect:

1. Practical Application of the Science: Our expert faculty educators will guide you through this engaging and informative program, and offer suggestions on how you can apply the latest science to patient care.
2. Patient-Centered Care: Learn from faculty who are directly involved in patient care about strategies for providing compassionate care that addresses individuals’ unique needs and challenges.
3. Team Focused: Explore how HIV clinicians from multiple professions are collaborating to optimize patient care.

• Explain the rationale for anal cancer screening.
• Identify populations at-risk and indications for screening based on current International Anal Neoplasia Society (IANS) and CDC guidelines.
• Collaborate as a healthcare team to identify appropriate screening tools and effectively perform anal cytology and digital anal rectal exams.

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NPs and Nurses:

American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours
(0.5 Pharmacotherapeutic Contact Hours).

California
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.

Physician Assistants

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until December 10, 2025. PAs should only claim credit commensurate with the extent of their participation.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other members of the care team will receive a certificate of participation.

Support

Support for this activity has been made possible through an educational grant from Gilead Sciences.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Educator/Planner Disclosures

Michael Gaisa, MD, PhD: discloses relevant relationships with Merck, ViiV Healthcare.
Naomi Jay, PhD, RN, NP: No relevant financial relationships to disclose.

Planning Team:

Jonathan Colasanti, MD; Courtney Fletcher, PharmD; Jose Gutierrez, PhD, FNP-BC; Asa E. Radix, MD, PhD, MPH; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Daiquiri Y. Robinson, MEd: No relevant financial relationships to disclose.
Roger Bedimo, MD, MS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Merck, Theratechnologies, Janssen, Shionogi; Grant/Research Support – Merck
William R. Short, MD, MPH: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences; Grant/Research Support – Gilead Sciences, Janssen*
H. Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Sarah Smith, MHS, PA-C, AAHIVS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Janssen, Merck; Speakers Bureau – ViiV Healthcare, Gilead Sciences, Janssen, Merck
*Relationship has ended.
This activity does not include information about off-label uses of approved agents and/or investigational agents.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy/ACTHIV® Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.